INFLECTION POINT ACQUISITION (BACQ) Fundamental Analysis & Valuation

NASDAQ:BACQ • KYG1169T1040

10.47 USD
0 (0%)
Last: Mar 6, 2026, 08:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BACQ fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to BACQ. BACQ was compared to 0 industry peers in the Unkown industry. BACQ scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BACQ is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. BACQ Profitability Analysis

1.1 Basic Checks

  • In the past year BACQ was profitable.
  • In the past year BACQ has reported a negative cash flow from operations.
BACQ Yearly Net Income VS EBIT VS OCF VS FCFBACQ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2024 0 500K 1M 1.5M

1.2 Ratios

Industry RankSector Rank
ROA 2.45%
ROE 2.57%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BACQ Yearly ROA, ROE, ROICBACQ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2024 0 0.2 0.4 0.6

1.3 Margins

  • BACQ does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BACQ Yearly Profit, Operating, Gross MarginsBACQ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BACQ Health Analysis

2.1 Basic Checks

  • BACQ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BACQ Yearly Shares OutstandingBACQ Yearly Shares OutstandingYearly Shares Outstanding 2024 10M 20M 30M
BACQ Yearly Total Debt VS Total AssetsBACQ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • BACQ has an Altman-Z score of 17.75. This indicates that BACQ is financially healthy and has little risk of bankruptcy at the moment.
  • There is no outstanding debt for BACQ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 17.75
ROIC/WACCN/A
WACCN/A
BACQ Yearly LT Debt VS Equity VS FCFBACQ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • BACQ has a Current Ratio of 0.43. This is a bad value and indicates that BACQ is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BACQ has a Quick Ratio of 0.43. This is a bad value and indicates that BACQ is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.43
Quick Ratio 0.43
BACQ Yearly Current Assets VS Current LiabilitesBACQ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2024 500K 1M 1.5M 2M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. BACQ Growth Analysis

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%278.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. BACQ Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 55.11, BACQ can be considered very expensive at the moment.
  • Compared to an average S&P500 Price/Earnings ratio of 26.29, BACQ is valued quite expensively.
Industry RankSector Rank
PE 55.11
Fwd PE N/A
BACQ Price Earnings VS Forward Price EarningsBACQ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BACQ Per share dataBACQ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BACQ Dividend Analysis

5.1 Amount

  • No dividends for BACQ!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BACQ Fundamentals: All Metrics, Ratios and Statistics

INFLECTION POINT ACQUISITION

NASDAQ:BACQ (3/6/2026, 8:01:50 PM)

10.47

0 (0%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-12
Earnings (Next)N/A
Inst Owners88.38%
Inst Owner Change-20.73%
Ins OwnersN/A
Ins Owner Change0%
Market Cap353.47M
Revenue(TTM)N/A
Net Income(TTM)6.41M
AnalystsN/A
Price TargetN/A
Short Float %0.13%
Short Ratio0.15
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 55.11
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.42
P/tB 1.42
EV/EBITDA N/A
EPS(TTM)0.19
EY1.81%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS7.38
TBVpS7.38
PEG (NY)N/A
PEG (5Y)N/A
Graham Number5.62
Profitability
Industry RankSector Rank
ROA 2.45%
ROE 2.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.43
Quick Ratio 0.43
Altman-Z 17.75
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%278.57%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

INFLECTION POINT ACQUISITION / BACQ FAQ

What is the fundamental rating for BACQ stock?

ChartMill assigns a fundamental rating of 1 / 10 to BACQ.


What is the valuation status for BACQ stock?

ChartMill assigns a valuation rating of 0 / 10 to INFLECTION POINT ACQUISITION (BACQ). This can be considered as Overvalued.


How profitable is INFLECTION POINT ACQUISITION (BACQ) stock?

INFLECTION POINT ACQUISITION (BACQ) has a profitability rating of 0 / 10.


Can you provide the financial health for BACQ stock?

The financial health rating of INFLECTION POINT ACQUISITION (BACQ) is 5 / 10.